Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Organon's score of 34 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Organon reported total carbon emissions of approximately 7,000,000 kg CO2e from Scope 1 and Scope 2, with Scope 1 emissions at about 2,272,000 kg CO2e and Scope 2 emissions at approximately 5,557,000 kg CO2e (market-based). Additionally, Scope 3 emissions were significant, with business travel contributing about 415,000 kg CO2e, employee commute at approximately 830,000 kg CO2e, and upstream and downstream transportation and distribution each at about 920,000 kg CO2e. Comparatively, in 2022, Organon's emissions were approximately 6,000,000 kg CO2e for Scope 1 and Scope 2, with Scope 1 at about 1,122,000 kg CO2e and Scope 2 at approximately 5,677,000 kg CO2e (market-based). Scope 3 emissions for that year included business travel at about 460,000 kg CO2e and employee commute at approximately 1,170,000 kg CO2e. Organon has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 GHG emissions by more than 25% from 2020 levels by 2025. This target reflects a commitment to sustainability and aligns with industry standards for climate action. The company is currently on track to meet this reduction goal, which is crucial for mitigating climate change impacts. Overall, Organon's emissions data and reduction initiatives demonstrate a proactive approach to addressing climate change, with a focus on significant emission sources across all scopes.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Organon has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
